| |
Article Title |
Author(s) |
Pages |
|
|
|
Highlights from the 5th Annual International Congress on Monoclonal Antibodies in Cancer Quebec City, Canada, August 2005 5th International Prostate Cancer Congress Rio Grande, Puerto Rico, July 2005 41st Annual Meeting of the American Society of Clinical Oncology Orlando, Florida, May 2005
|
G. Kesava Reddy,
Preeta Tyagi,
Eric Nadler,
Vinay K. Jain
|
73-78
|
|
|
|
Potential Role of Inhibiting the Vascular Endothelial Growth Factor Pathway in Advanced Prostate Cancer
|
Preeta Tyagi,
Eric Nadler,
Arif Hussain
|
80-82
|
|
|
|
Early Clinical Data and Potential Clinical Utility of Novel Histone Deacetylase Inhibitors in Prostate Cancer
|
G. Kesava Reddy,
Eric Nadler,
Arif Hussain
|
83-85
|
|
|
|
Second-Line Chemotherapy for Prostate Cancer: Patient Characteristics and Survival
Abstract: Purpose: First-line chemotherapy with docetaxel in patients with progressive castrate metastatic prostate cancer has been shown to improve overall survival compared with mitoxantrone-based t...
|
Kathleen W. Beekman,
Mark T. Fleming,
Howard I. Scher,
Susan F. Slovin,
Nicole M. Ishill,
Glenn Heller,
W. Kevin Kelly
et al.
|
86-90
|
|
|
|
Safety and Tolerability of PCK3145, a Synthetic Peptide Derived from Prostate Secretory Protein 94 (PSP94) in Metastatic Hormone-Refractory Prostate Cancer
Abstract: Background: The safety, tolerability, and pharmacokinetic and preliminary efficacy of PCK3145 were determined in patients with metastatic hormone-refractory prostate cancer. Patients and Met...
|
Robert E. Hawkins,
Luc Daigneault,
Richard Cowan,
Richard Griffiths,
Chandra Panchal,
Anne Armstrong,
Jackie Fenemore,
Alan Irvine,
Kasia Sereda,
Hélène Dulude
et al.
|
91-99
|
|
|
|
A Measure of Health-Related Quality of Life Among Patients with Localized Prostate Cancer: Results from Ongoing Scale Development
Abstract: Background: We revised our prostate cancer–specific measure to better address the physiologic complications of the 3 major therapies for clinically localized prostate cancer and to assess th...
|
Christie A. Befort,
Michael J. Zelefsky,
Peter T. Scardino,
Evelinn Borrayo,
R. Brian Giesler,
Michael W. Kattan
et al.
|
100-108
|
|
|
|
Quantitative Computed Tomography Perfusion of Prostate Cancer: Correlation with Whole-Mount Pathology
Abstract: Purpose: Microvessel density within the prostate is associated with presence of cancer, disease stage, and disease-specific survival. We evaluated multidetector computed tomography (CT) to e...
|
Elizabeth P. Ives,
Melissa A. Burke,
Pamela R. Edmonds,
Leonard G. Gomella,
Ethan J. Halpern
et al.
|
109-112
|
|
|
|
Prior Estrogen Therapy as a Predictor of Response to Subsequent Estramustine-Based Chemotherapy in Patients with Androgen-Independent Prostate Cancer
Abstract: Background: Hormone-refractory prostate cancer (HRPC) has modest response rates to second-line estrogenic agents such as diethylstilbestrol and the herbal product PC SPES. Estramustine phosp...
|
Jorge A. Garcia,
Vivian Weinberg,
Eric J. Small
|
113-117
|
|
|
|
Prostate-Specific Membrane Antigen Vaccines: Naked DNA and Protein Approaches
Abstract: Prostate-specific membrane antigen (PSMA) is a relatively omnipresent molecule with a multiplicity of functions and has been shown to be a reasonable target for immunologic approaches such a...
|
Susan F. Slovin
|
118-123
|
|
|
|
Molecular Effects of the Isoflavonoid Genistein in Prostate Cancer
Abstract: Differences in diet have been proposed to be at least partially responsible for the low rate of prostate cancer in Asian populations compared with men in Western countries. One of the compou...
|
Jasmin Bektic,
Roman Guggenberger,
Iris E. Eder,
Alexandre E. Pelzer,
Andreas P. Berger,
Georg Bartsch,
Helmut Klocker
et al.
|
124-129
|
|
|
|
Recent Trends in Surgical Treatment of Localized Prostate Cancer
Abstract: Prostate cancer and its various forms of treatment remain a source of significant controversy and morbidity despite recent advances. In response, there is an increasing trend toward the deve...
|
Brian A. Link,
Daniel J. Culkin
|
130-133
|
|
|
|
Orbital Metastasis from Prostate Cancer: An Atypical Case of Neuroendocrine Dedifferentiation During Progression from Hormone-Sensitive to Refractory Stage
Abstract: We report a case of orbital metastasis from a neuroendocrine dedifferentiated prostate cancer during progression from hormone-sensitive to hormone refractory stage. A patient receiving andro...
|
Suneetha Challagundla,
Murat Gokden,
Sanjaya Viswamitra,
Manish Kohli
|
134-137
|
|
|
|
A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
|
Elisabeth I. Heath,
Melvin Gaskins,
Henry C. Pitot,
Roberto Pili,
Winston Tan,
Robert Marschke,
Glenn Liu,
David Hillman,
Fazlul Sarkar,
Shijie Sheng,
Charles Erlichman,
Percy Ivy
et al.
|
138-141
|
|
|
|
Selected Clinical Trials In Prostate Cancer
|
|
142
|
|
